Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A multimodal analgesic combination used for patient-controlled intravenous analgesia (PCIA) in postoperative pain management. This combination leverages the complementary mechanisms of action of its components: dexmedetomidine (a highly selective α2-adrenergic receptor agonist with sedative and analgesic properties), tramadol (an opioid with μ-receptor agonist activity and serotonin/norepinephrine reuptake inhibition), and flurbiprofen (a nonsteroidal anti-inflammatory drug). The combination aims to provide effective pain relief while potentially reducing opioid-related side effects and improving patient outcomes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexmedetomidine + tramadol + flurbiprofen.